LARGE B-CELL LYMPHOMA

This phase 2 trial tests a combination of three drugs—glofitamab, a PD-1 inhibitor, and lenalidomide—in 24 adults with relapsed or refractory large B-cell lymphoma that has a TP53 gene mutation. The goal is to see if this mix can shrink tumors or make them disappear. The study is…

This phase 2 trial tests a new CAR T-cell therapy called WZTL-002 for people with large B-cell lymphoma that has returned or not responded to standard treatment. About 60 participants will receive the therapy after a short course of chemotherapy. Researchers will track how many a…

This study tests a new treatment called rondecabtagene autoleucel (ronde-cel) for people with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. Ronde-cel is a CAR T-cell therapy that targets two proteins (CD19 and CD20) on cancer cells. …

This phase II trial tests whether the drug loncastuximab tesirine (Lonca) can help control large B-cell lymphoma in patients who had only a partial response after CAR T-cell therapy. About 30 adults with relapsed or refractory lymphoma will receive Lonca intravenously. The main g…

This early-phase study is testing whether a second infusion of the CAR T-cell therapy axicabtagene ciloleucel (Axi-Cel-2) is safe for adults with high-risk large B-cell lymphoma whose cancer came back or didn't respond to the first standard CAR T treatment. About 20 participants …

This early-phase study tests whether a drug called NT-I7 can safely boost the effects of CAR T-cell therapy in people with large B-cell lymphoma that has come back or not responded to treatment. About 24 participants will receive NT-I7 after standard CAR T therapy. The goal is to…

This phase 3 trial tests a new CAR T-cell therapy called rondecabtagene autoleucel (ronde-cel) that targets two proteins (CD19 and CD20) on lymphoma cells. It is compared to standard CD19-targeting CAR T-cell therapy in 400 patients with relapsed or refractory large B-cell lympho…

This early-stage study tests a new gene therapy called VNX-101 for people with blood cancers (like some leukemias and lymphomas) that have returned or not responded to standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system target and…

This study tests whether giving an extra antibody drug after CAR-T cell therapy can improve outcomes for people with aggressive large B-cell lymphoma that has come back or not responded to prior treatments. About 23 participants will receive either mosunetuzumab or glofitamab (pl…

This study tests whether adding the drug epcoritamab to a standard, gentler chemotherapy mix (R-miniCVP) can help control newly diagnosed diffuse large B-cell lymphoma in older or frail adults who cannot tolerate stronger chemo. About 40 participants will receive the combination …

This study tests a new cell therapy called cemacabtagene ansegedleucel (cema-cel) in adults with large B-cell lymphoma who still have tiny amounts of cancer cells (minimal residual disease) after finishing their first standard treatment. About 250 participants will be randomly as…

This study tests whether giving focused radiation to large tumors before CAR-T cell therapy can help control aggressive large B-cell lymphoma that has come back or not responded to treatment. About 27 adults with tumors at least 5 cm will receive this combination. The goal is to …

This study aims to find out which factors help predict whether CAR-T therapy will work in people with relapsed or refractory large B-cell lymphoma. Researchers will look at patient health records, tumor features, and immune system changes in 80 participants. The goal is to better…

This study looks back at medical records of about 250 adults with large B-cell lymphoma who received the drug Glofitamab through a special access program in France. The goal is to see how well the drug works and what side effects occur in everyday practice, especially in patients…

This study is testing a new communication training program called Hematolo-GIST for doctors who treat large B-cell lymphoma. The goal is to help doctors better discuss the diagnosis and plan future care with their patients. About 48 people (doctors and patients) will take part to…